Abstract:The transplantation of conventional human cell and tissue grafts, such as heart valve replacements and skin for severely burnt patients, has saved many lives over the last decades. The late eighties saw the emergence of tissue engineering with the focus on the development of biological substitutes that restore or improve tissue function. In the nineties, at the height of the tissue engineering hype, industry incited policymakers to create a European regulatory environment, which would facilitate the emergence of a strong single market for tissue engineered products and their starting materials (human cells and tissues). In this paper we analyze the elaboration process of this new European Union (EU) human cell and tissue product regulatory regime-i.e. the EU Cell and Tissue Directives (EUCTDs) and the Advanced Therapy Medicinal Product (ATMP) Regulation and evaluate its impact on Member States' health care systems. We demonstrate that the successful lobbying on key areas of regulatory and policy processes by industry, in congruence with Europe's risk aversion and urge to promote growth and jobs, led to excessively business oriented legislation. Expensive industry oriented requirements were introduced and contentious social and ethical issues were excluded. We found indications that this new EU safety and health legislation will adversely impact Member States' health care systems; since 30 December 2012 (the end of the ATMP transitional period) there is a clear threat to the sustainability of some lifesaving and established ATMPs that were provided by public health institutions and small and medium-sized enterprises under the frame of the EUCTDs. In the light of the current economic crisis it is not clear how social security systems will cope with the inflation of costs associated with this new regulatory regime and how priorities will be set with regard to reimbursement decisions. We argue that the ATMP Regulation should urgently be revised to focus on delivering affordable therapies to all who are in need of them and this without necessarily going to the market. The most rapid and elegant way to achieve this would be for the European Commission to publish an interpretative document on "placing on the market of ATMPs," which keeps tailor-made and niche ATMPs outside of the scope of the medicinal product regulation.

Tissue engineered constructs: perspectives on clinical translation

Clinical Translation of Biomedical Materials and the Key Factors Towards Product Registration

Organizational aspects of tissue engineering clinical translation: insights from a qualitative case study

[Supervision, Administration and Standard Research Related to Tissue Engineered Medical Products].

Tissue Engineering and Regenerative Medicine: History, Progress, and Challenges

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective

Clinical Translation of Autologous Cell-Based Tissue Engineering Techniques As Class III Therapeutics in China: Taking Cartilage Tissue Engineering As an Example

Key considerations on the development of biodegradable biomaterials for clinical translation of medical devices: With cartilage repair products as an example

Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate

Regulation Challenge of Tissue Engineering and Regenerative Medicine in China

[Tissue Engineered Skin and Regenerative Wound Repair].

Stem Cell Therapy: From Idea to Clinical Practice

Clinical Application for Tissue Engineering Focused on Materials

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

Current and Future Perspectives on Skin Tissue Engineering: Key Features of Biomedical Research, Translational Assessment, and Clinical Application

From Promise to Practice: Recent Growth in 30 Years of Tissue Engineering Commercialization

From bench to FDA to bedside: US regulatory trends for new stem cell therapies

Prospects for Translational Regenerative Medicine

Stem cell differentiation and expansion for clinical applications of tissue engineering.

The Expanding World of Tissue Engineering: The Building Blocks and New Applications of Tissue Engineered Constructs

Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems